<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39331372</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2689-0186</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>JAMA health forum</Title><ISOAbbreviation>JAMA Health Forum</ISOAbbreviation></Journal><ArticleTitle>Menopausal Hormone Therapy Use Among Postmenopausal Women.</ArticleTitle><Pagination><StartPage>e243128</StartPage><MedlinePgn>e243128</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e243128</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamahealthforum.2024.3128</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Menopausal hormone therapy (MHT) is the treatment of choice for symptoms of menopause. However, its adoption is hindered by the risk-benefit trade-off in relation to acute and chronic diseases.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate trends in and correlates of MHT use among postmenopausal women in the US from 1999 to March 2020.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This serial cross-sectional analysis of MHT use used data from the nationally representative National Health and Nutrition Examination Survey (NHANES). Participants included noninstitutionalized US postmenopausal women from 10 NHANES study cycles (1999-2000 to 2017-March 2020 [pre-COVID-19 pandemic]). Data were analyzed from December 2023 to April 2024.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="UNASSIGNED">NHANES study cycle.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">Prevalence of MHT use was extracted from the prescription medication data collected during NHANES household interviews. MHT formulations were determined by hormone type.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Data on 13 048 US postmenopausal women (47.1% ≥65 years old) were analyzed. From 1999 to 2020, the prevalence of MHT use decreased among women of all age groups, from 26.9% (95% CI, 22.6%-31.7%) in 1999 to 4.7% (95% CI, 3.4%-6.5%) in 2020. Until 2002, MHT use was highest among women aged 52 to 65 years, but since 2005, MHT use has been highest among women younger than 52 years. MHT use decreased by 23.5% (95% CI, 11.4%-35.6%), 31.4% (95% CI, 23.4%-39.5%), and 10.6% (95% CI, 6.3%-14.8%) for women younger than 52 years, 52 years to younger than 65 years, and 65 years and older, respectively. Prevalence of MHT use decreased from 13.8% (95% CI, 8.5%-21.7%) to 2.6% (95% CI, 1.5%-4.6%) for Hispanic women, 11.9% (95% CI, 8.5%-16.3%) to 0.5% (95% CI, 0.2%-1.1%) for non-Hispanic Black women, and 31.4% (95% CI, 27.1%-36.1%) to 5.8% (95% CI, 4.1%-8.2%) for non-Hispanic White women. Non-Hispanic White women consistently had the highest prevalence of MHT use. Estrogen-only formulation accounted for more than 50% of the MHT for most study periods. The prevalence of MHT use varied by family income-to-poverty ratio, health insurance coverage in all racial and ethnic groups, weight, and smoking status among non-Hispanic White women, as well as by education attainment among non-Hispanic Black and Hispanic women.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">Results of this cross-sectional study show that over the past 2 decades, MHT use declined among US postmenopausal women of all age and racial and ethnic groups. Women of racial and ethnic minority groups had lower prevalence of MHT use compared to non-Hispanic White women.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cancer Epidemiology and Prevention Research, Cancer Research and Analytics, Cancer Care Alberta, Alberta Health Services, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toriola</LastName><ForeName>Adetunji T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Health Forum</MedlineTA><NlmUniqueID>101769500</NlmUniqueID><ISSNLinking>2689-0186</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamahealthforum.2024.3135</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017698" MajorTopicYN="Y">Postmenopause</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009749" MajorTopicYN="Y">Nutrition Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015914" MajorTopicYN="Y">Estrogen Replacement Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Yang reported grants from the Canadian Institutes of Health Research and the Canadian Cancer Society during the conduct of the study. Dr Toriola reported grants from the National Cancer Institute during the conduct of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331372</ArticleId><ArticleId IdType="pmc">PMC11437377</ArticleId><ArticleId IdType="doi">10.1001/jamahealthforum.2024.3128</ArticleId><ArticleId IdType="pii">2823976</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peacock K, Carlson K, Ketvertis KM. Menopause. StatPearls Publishing; 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">29939603</ArticleId></ArticleIdList></Reference><Reference><Citation>Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: a review. JAMA. 2023;329(5):405-420. doi:10.1001/jama.2022.24140</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.24140</ArticleId><ArticleId IdType="pubmed">36749328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold EB, Colvin A, Avis N, et al. . Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health. 2006;96(7):1226-1235. doi:10.2105/AJPH.2005.066936</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2005.066936</ArticleId><ArticleId IdType="pmc">PMC1483882</ArticleId><ArticleId IdType="pubmed">16735636</ArticleId></ArticleIdList></Reference><Reference><Citation>The North American Menopause Society Advisory Panel . The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GME.0000000000002028</ArticleId><ArticleId IdType="pubmed">35797481</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999;130(7):545-553. doi:10.7326/0003-4819-130-7-199904060-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-130-7-199904060-00002</ArticleId><ArticleId IdType="pubmed">10189323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho L, Kaunitz AM, Faubion SS, et al. ; ACC CVD in Women Committee . Rethinking menopausal hormone therapy: for whom, what, when, and how long? Circulation. 2023;147(7):597-610. doi:10.1161/CIRCULATIONAHA.122.061559</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.061559</ArticleId><ArticleId IdType="pmc">PMC10708894</ArticleId><ArticleId IdType="pubmed">36780393</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol. 2012;120(3):595-603. doi:10.1097/AOG.0b013e318265df42</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0b013e318265df42</ArticleId><ArticleId IdType="pmc">PMC3607288</ArticleId><ArticleId IdType="pubmed">22914469</ArticleId></ArticleIdList></Reference><Reference><Citation>ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216. doi:10.1097/01.AOG.0000441353.20693.78</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.AOG.0000441353.20693.78</ArticleId><ArticleId IdType="pubmed">24463691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee . American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause—2017 update. Endocr Pract. 2017;23(7):869-880. doi:10.4158/EP171828.PS</Citation><ArticleIdList><ArticleId IdType="doi">10.4158/EP171828.PS</ArticleId><ArticleId IdType="pubmed">28703650</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangione CM, Barry MJ, Nicholson WK, et al. ; US Preventive Services Task Force . Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US Preventive Services Task Force recommendation statement. JAMA. 2022;328(17):1740-1746. doi:10.1001/jama.2022.18625</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18625</ArticleId><ArticleId IdType="pubmed">36318127</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health and Nutrition Examination Survey. Centers for Disease Control and Prevention . Accessed February 10, 2014. https://www.cdc.gov/nchs/nhanes.htm</Citation></Reference><Reference><Citation>Akinbami LJ, Chen TC, Davy O, et al. . National Health and Nutrition Examination Survey, 2017-March 2020 prepandemic file: sample design, estimation, and analytic guidelines. Vital Health Stat 1. 2022;2(190):1-36. doi:10.15620/cdc:115434</Citation><ArticleIdList><ArticleId IdType="doi">10.15620/cdc:115434</ArticleId><ArticleId IdType="pubmed">35593699</ArticleId></ArticleIdList></Reference><Reference><Citation>NHANES questionnaires, datasets, and related documentation. Centers for Disease Control and Prevention . Accessed March 19, 2024. https://wwwn.cdc.gov/nchs/nhanes/</Citation></Reference><Reference><Citation>Appiah D, Nwabuo CC, Ebong IA, Wellons MF, Winters SJ. Trends in age at natural menopause and reproductive life span among US women, 1959-2018. JAMA. 2021;325(13):1328-1330. doi:10.1001/jama.2021.0278</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0278</ArticleId><ArticleId IdType="pmc">PMC8025101</ArticleId><ArticleId IdType="pubmed">33821908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaunitz AM, Kapoor E, Faubion S. Treatment of women after bilateral salpingo-oophorectomy performed prior to natural menopause. JAMA. 2021;326(14):1429-1430. doi:10.1001/jama.2021.3305</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3305</ArticleId><ArticleId IdType="pmc">PMC8792973</ArticleId><ArticleId IdType="pubmed">34636868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu FB, Grodstein F, Hennekens CH, et al. . Age at natural menopause and risk of cardiovascular disease. Arch Intern Med. 1999;159(10):1061-1066. doi:10.1001/archinte.159.10.1061</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.159.10.1061</ArticleId><ArticleId IdType="pubmed">10335682</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health and Nutrition Examination Survey 1988-2020 data documentation, codebook, and frequencies: prescription medications—drug information (RXQ_DRUG). Centers for Disease Control and Prevention . Accessed February 10, 2024. https://wwwn.cdc.gov/Nchs/Nhanes/1999-2000/RXQ_DRUG.htm</Citation></Reference><Reference><Citation>National Institutes of Health . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res. 1998;6(suppl 2):51S-209S.</Citation><ArticleIdList><ArticleId IdType="pubmed">9813653</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtin LR, Mohadjer LK, Dohrmann SM, et al. . The National Health and Nutrition Examination Survey: sample design, 1999-2006. Vital Health Stat 2. 2012;(155):1-39.</Citation><ArticleIdList><ArticleId IdType="pubmed">22788053</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause. 2011;18(4):385-392. doi:10.1097/gme.0b013e3181f43404</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/gme.0b013e3181f43404</ArticleId><ArticleId IdType="pmc">PMC3123410</ArticleId><ArticleId IdType="pubmed">21127439</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford SL, Crandall CJ, Derby CA, et al. . Menopausal hormone therapy trends before versus after 2002: impact of the Women’s Health Initiative Study results. Menopause. 2018;26(6):588-597. doi:10.1097/GME.0000000000001282</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GME.0000000000001282</ArticleId><ArticleId IdType="pmc">PMC6538484</ArticleId><ArticleId IdType="pubmed">30586004</ArticleId></ArticleIdList></Reference><Reference><Citation>Clanget C, Hinke V, Lange S, Fricke R, Botko R, Pfeilschifter J. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women: changes after HERS II and WHI. Exp Clin Endocrinol Diabetes. 2005;113(9):529-533. doi:10.1055/s-2005-865802</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2005-865802</ArticleId><ArticleId IdType="pubmed">16235155</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinig M, Braitmaier M, Haug U. Prescribing of menopausal hormone therapy in Germany: current status and changes between 2004 and 2016. Pharmacoepidemiol Drug Saf. 2021;30(4):462-471. doi:10.1002/pds.5186</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5186</ArticleId><ArticleId IdType="pubmed">33368726</ArticleId></ArticleIdList></Reference><Reference><Citation>Park CY, Lim JY, Kim WH, Kim SY, Park HY. Evaluation of menopausal hormone therapy use in Korea (2002-2013): a nationwide cohort study. Maturitas. 2021;146:57-62. doi:10.1016/j.maturitas.2021.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2021.02.003</ArticleId><ArticleId IdType="pubmed">33722365</ArticleId></ArticleIdList></Reference><Reference><Citation>Velentzis LS, Egger S, Banks E, Canfell K. Menopausal hormone therapy: characterising users in an Australian national cross-sectional study. PLoS One. 2021;16(8):e0253725. doi:10.1371/journal.pone.0253725</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253725</ArticleId><ArticleId IdType="pmc">PMC8357145</ArticleId><ArticleId IdType="pubmed">34379634</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsugeir D, Wei L, Adesuyan M, Cook S, Panay N, Brauer R. Hormone replacement therapy prescribing in menopausal women in the UK: a descriptive study. BJGP Open. 2022;6(4):BJGPO.2022.0126. doi:10.3399/BJGPO.2022.0126</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/BJGPO.2022.0126</ArticleId><ArticleId IdType="pmc">PMC9904798</ArticleId><ArticleId IdType="pubmed">36216368</ArticleId></ArticleIdList></Reference><Reference><Citation>Chlebowski RT, Anderson GL, Aragaki AK, et al. . Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020;324(4):369-380. doi:10.1001/jama.2020.9482</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.9482</ArticleId><ArticleId IdType="pmc">PMC7388026</ArticleId><ArticleId IdType="pubmed">32721007</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlow SD, Burnett-Bowie SM, Greendale GA, et al. . Disparities in reproductive aging and midlife health between Black and White women: the Study of Women’s Health Across the Nation (SWAN). Womens Midlife Health. 2022;8(1):3. doi:10.1186/s40695-022-00073-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40695-022-00073-y</ArticleId><ArticleId IdType="pmc">PMC8822825</ArticleId><ArticleId IdType="pubmed">35130984</ArticleId></ArticleIdList></Reference><Reference><Citation>Faubion SS, Enders F, Hedges MS, et al. . Impact of menopause symptoms on women in the workplace. Mayo Clin Proc. 2023;98(6):833-845. doi:10.1016/j.mayocp.2023.02.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2023.02.025</ArticleId><ArticleId IdType="pubmed">37115119</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>